Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
Shilpa Biologicals, part of the Shilpa Medicare Group, said the biologic is a first-in-class, immunology-driven therapy ...
Japanese drugmaker Chugai today revealed it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody ...
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI ...
Nipah outbreaks have occurred almost annually in Asia, particularly in Bangladesh and India. Cases have also been reported in ...
Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...
The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough ...
DARZALEX FASPRO ® U.S. Prescribing Information. 2 Johnson & Johnson Innovative Medicine. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet ...
A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results